coteau ARQ.

NKTR

$39.22
+$0.00 (0.00%) Oct 21 close
Sector n/a CompareTechnicals
1M3M6M1Y2Y
-44%-18%+8%+33%+59%Oct 2025Oct 2026Apr 202652w high $100.3552w low $35.12
NKTRSPY
Wall St. Highest PT $127.32 (+224.6%) Wall St. Avg PT $104.36 (+166.1%)
$35$70$105$139$174POC $75Hi $127Avg $104
Underwater Drawdown %Max DD -64.3%Current -60.9%
0.0%-64.3%
Relative Strength vs SPY-54.1% vs SPYUnderperforming
+67%0%-67%
1W
+$2.33 (6.32%)
1M
−$27.62 (41.32%)
3M
−$30.10 (43.42%)
6M
−$53.98 (57.92%)
YTD
−$3.06 (7.24%)
1Y
−$20.16 (33.95%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for NKTR
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

52-week range$35.12 – $100.35

What they do

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NKTR yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

Next report: –
No EPS history available.

News & catalysts

More news
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Oct 23

Stats refreshed – ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026